Axim Biotech (AXIM)

Executive Summary

Axim Biotech is a vertically integrated diagnostics company specializing in rapid point-of-care tests for ophthalmological conditions, particularly Dry Eye Disease (DED). Founded in 2014 and headquartered in New York, the company aims to address the significant unmet need for accurate, rapid diagnosis of DED, which affects millions worldwide and is often underdiagnosed. Axim's proprietary diagnostic platform leverages advanced biomarker detection to deliver results within minutes, enabling earlier intervention and improved patient outcomes. Despite a modest valuation of approximately $1.9 million and limited public data, the company's focus on a high-demand niche positions it for potential growth. However, Axim faces challenges common to early-stage diagnostics firms, including regulatory hurdles, clinical validation requirements, and competition from established players.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) submission for DED rapid diagnostic test70% success
• Q4 2026Commercial partnership with a major ophthalmology distributor50% success
• Q2 2026Publication of clinical validation study results in a peer-reviewed journal80% success